Figure 2. PBN: spin-trapping activity and hydrophilic derivatives.
Figure 1. Pyrrolidine iminosugars and N-oxy analogues.
N-hydroxy-pyrrolidines6g,8 (II) have been reported. Remark-
ably, only a single letter describes the obtention of a
polyhydroxylated endocyclic nitrone, in the course of
structural studies on the enediyne antibiotic esperamycin A1.9
Nitrones share with imines10,11 the sp2 character at the
pseudoanomeric position (beneficial to mimic oxocarbenium-
like transition states) and with tertiary amine N-oxides the
zwitterionic character.12 Notwithstanding these potentially
advantageous properties, the biological activity of polyhy-
droxylated nitrones related to iminosugars has never been
evaluated, although numerous polyalkoxylated nitrones have
been used by chemists as synthetic intermediates.13
In addition, nitrones have been recognized as protective
agents against oxidative stress in biological systems.14 While
R-phenyl-N-tert-butylnitrone (PBN) is the most studied
nitrone with respect to spin-trapping properties,15 several
hydrophilic derivatives, such as NXY-05916 and LPBNAH,17
have been designed for better distribution (Figure 2).
Interestingly, the activity of nitrones as antioxidants is
dependent on their lipophilicity/hydrophilicity balance as
recently demonstrated by the group of Pucci.18 Highly water-
soluble nitrones are still scarce in the literature, and their
physicochemical properties have not been investigated in
detail.
In this paper, we disclose a method to prepare polyhy-
droxylated cyclic nitrones from polyalkoxy precursors that
are themselves readily prepared from commercially available
carbohydrates.13 Such cyclic nitrones are generally prepared
by (i) introduction of ethers or isopropylidene ketals to
protect hydroxyl groups in carbohydrates and (ii) cyclization
by intramolecular N-alkylation of an oxime function placed
at the anomeric center. Benzyl ethers have proved particularly
convenient in such sequences, as benzyl groups are stable
to a large variety of chemical treatments but can be removed
by hydrogenolysis.19 Consequently, benzyl protection of
hydroxyl groups has been commonly used for the synthesis
of carbohydrate-derived nitrones.13,20
(7) (a) Humphrey, A. J.; Parsons, S. F.; Smith, M. E. B.; Turner, N. J.
Tetrahedron Lett. 2000, 41, 4481. (b) Palmer, A. M.; Ja¨ger, V. Synlett 2000,
1405. (c) O’Neil, I. A.; Cleator, E.; Hone, N.; Southern, J. M.; Tapolczay,
D. J. Synlett 2000, 1408. (d) Laventine, D. M.; Davies, M.; Evinson, E. L.;
Jenkins, P. R.; Cullis, P. M.; Fawcett, J. Tetrahedron Lett. 2005, 46, 307.
(8) (a) Kajimoto, T.; Liu, K. K.-C.; Pederson, R. L.; Zhong, Z.; Ishikawa,
Y.; Porco, J. A., Jr; Wong, C.-H. J. Am. Chem. Soc. 1991, 113, 6187. (b)
Palmer, A. M.; Ja¨ger, V. Eur. J. Org. Chem. 2001, 66, 1293. (c) Palmer,
A. M.; Ja¨ger, V. Eur. J. Org. Chem. 2001, 66, 2547.
The deprotection of benzyloxy-substituted nitrones could
not be effected by hydrogenolysis as the nitrone functionality
does not resist such conditions.21 We thus considered another
method for benzyl ether cleavage, previously used in
carbohydrate chemistry, that involves treatment of benzyl
ethers with boron trichloride.22 It should be noted that
substrates containing nitrone or hydroxylamine functions
have never been subjected to such treatment. At first, this
(9) Golik, J.; Wong, H.; Krishnan, B.; Vyas, D. M.; Doyle, T. W.
Tetrahedron Lett. 1991, 32, 1851.
(10) Sugar imines have shown enhanced inhibitory properties over their
fully reduced counterparts: (a) Wong, C.-H.; Provencher, L.; Porco, J. A.;
Jung, S.-H.; Wang, Y.-F.; Chen, L.; Wang, R.; Steensma, D. H. J. Org.
Chem. 1995, 60, 1492. (b) Takayama, S.; Martin, R.; Wu, J. Y.; Laslo, K.;
(16) Nitrone NXY-059 (Astra Zeneca) has been in phase III clinical trials
as a neuroprotective agents for the treatment of cerebral ischemias: (a) Lapchak,
P. A.; Song, D.; Wei, J.; Zivin, J. A. Exp. Neurol. 2004, 188, 279.
(17) Poeggeler, B.; Durand, G.; Polidori, A.; Pappolla, M. A.; Vega-
Naredo, I.; Coto-Montes, A.; Bo¨cker, J.; Hardeland, R.; Pucci, B. J. Neu-
rochem. 2005, 95, 962.
Siuzdak, G.; Wong, C.-H. J. Am. Chem. Soc. 1997, 119, 8146
.
(11) Nectrisine (FR-900484) is an example of potent R-mannosidase
and glucosidase inhibitor, exhibiting immunomodulator activity: (a) Hibata,
T.; Nakayama, O.; Tsurumi, Y.; Okuhara, M.; Terano; H.; Ohsaka, M. J.
Antibiot. 1988, 41, 296. (b) Kim, Y. J.; Takatsuki, A.; Kogoshi, N.; Kitahara,
(18) Durand, G.; Poeggeler, B.; Bo¨ker, J.; Raynal, S.; Polidori, A.;
Pappolla, M. A.; Hardeland, R.; Pucci, B. J. Med. Chem. 2007, 50, 3976.
(19) Wuts, P. G. M.; Greene, T. W. Greene’s ProtectiVe Groups in
Organic Synthesis; Wiley Interscience: New York, 2007.
T. Tetrahedron 1999, 55, 8353
.
(12) Such zwitterionic character was proposed to allow better interaction
with the putative carboxylate and carboxylic acid residues in active sites
of glycosidases due to stronger electrostatic interactions. However, this
hypothesis has yet to be validated as the previously prepared polyhydroxy-
lated piperidine and pyrrolidine N-oxides exhibited weak or unsignificant
activity against glycosidases: (a) Dong, W.; Jespersen, T.; Bols, M.;
Skrydstrup, T.; Sierk, M. R. Biochemistry 1996, 35, 2788. See also ref 8a,
c.
(20) For examples from our laboratory, see: (a) Desvergnes, S.; Py, S.;
Valle´e, Y. J. Org. Chem. 2005, 70, 1459. (b) Desvergnes, S.; Desvergnes,
V.; Martin, O. R.; Itoh, K.; Liu, H-w.; Py, S. Bioorg. Med. Chem. 2007,
15, 6443. (c) Pillard, C.; Desvergnes, V.; Py, S. Tetrahedron Lett. 2007,
48, 6209
.
(21) (a) Oppolzer, W.; Merifield, E. HelV. Chim. Acta 1993, 76, 957.
(b) Murahashi, S.-I.; Tsuji, T.; Ito, S. Chem. Commun. 2000, 409. (c) Baillie,
L. C.; Bearder, J. R.; Sherringham, J. A.; Whiting, D. A. J. Chem. Soc.,
Perkin Trans. 1 1997, 2687. (d) Broggini, G.; Zecchi, G. Tetrahedron:
Asymmetry 1997, 8, 1431. (e) Broggini, G.; Zecchi, G. Synthesis 1996, 1280.
(f) Ali, S. A.; Wazeer, M. I. M. Tetrahedron 1993, 49, 4339. (g) Duvall,
J. R.; Wu, F.; Snider, B. B. J. Org. Chem. 2006, 71, 8579.
(13) For a recent review on enantiopure, carbohydrate-derived cyclic
nitrones, see: (a) Revuelta, J.; Cicchi, S.; Goti, A.; Brandi, A. Synthesis
2007, 485.
(14) For a review, see: (a) Floyd, R. A. AdV. Pharm. 1997, 38, 361.
(15) Janzen, E. G.; Kotake, Y.; Hinton, R. D. Free Radical Biol. Med.
1992, 12, 169, and references therein.
2968
Org. Lett., Vol. 10, No. 14, 2008